NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression

NorthStrive Biosciences Inc., a subdivision of PMGC Holdings Inc., announced plans to initiate an autonomous flow cytometry, or FACS, analysis program to further characterize EL-22, the Company’s engineered Lactobacillus casei-driven medicinal candidate intended to express a latent myostatin antigen to support preserving muscle while weight loss management, involving GLP-1 receptor agonists.

An independent flow cytometry (FACS) research quantifies latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establishes comparability against EL-22 material previously manufactured by MOA Life Plus Co., Ltd.

Work is designed to strengthen the EL-22 product's detection and production consistency as NorthStrive advances a distinguished engineered probiotic designed to supports preserve muscle during weight loss, involving GLP-1 receptor agonists.

Establishing Manufacturing Comparability

The planned research is designed to offer a quantitative measurement of target antigen expression on NorthStrive-manufactured L. casei cells and support comparability analysis against material previously manufactured by MOA Life Plus Co., Ltd. NorthStrive believes this work signifies a significant step in building a stronger analytical and manufacturing description package for EL-22.

Study Design

The FACS analysis is likely to estimate a panel of Lactobacillus samples, involving NorthStrive-manufactured material and proper controls, using antibody-driven identification and live or dead cell analysis. The aim is to create reproducible quantitative information on target antigen expression at the bacterial cell surface and in the specific cells, significant measures for product detection, production consistency, and comparability.

The organization expects to work with an autonomous contract research organization specializing in flow cytometry analysis. The planned work is expected to involve antibody conjugation, live or dead marker analysis, sample testing, and information generation in the sample panel.

Development Objectives

NorthStrive believes this analytical program helps numerous significant advancement objectives:

• Quantifying latent myostatin antigen expression on engineered L. casei cells.
• Comparing NorthStrive-manufactured EL-22 material against earlier-manufactured material.
• Strengthening the organization’s product detection and production consistency package.
• Supporting future analytical method development and comparability assessments.
• Building the product characterization foundation for future IND-enabling development of EL-22.

According to Towards Healthcare, the flow cytometry market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 5.33 billion in 2026 to approximately USD 9.80 billion by 2035, representing a compound annual growth rate (CAGR) of 7% from 2026 to 2035, driven by the fact that flow cytometry provides increasing sensitivity for feasibility assays, capable of identifying indirect variations in cell viability. Flow cytometry allows quantification of viable and non-viable cells in a population.

By using fluorescent dyes that selectively label either live or dead cells, flow cytometry offers precise and reliable viability dimensions, facilitating the determination of cell viability percentages. Flow cytometry is a transformative tool in modern medicine, allowing thorough and exact analysis of cells for the diagnosis, monitoring, and management of different diseases. Flow cytometry, used in tumor diagnostics, immunology, or hematology, offers significant insights into the underlying mechanisms of disease, supporting healthcare providers to make informed decisions for patient care. With the increasing uses and advantages, flow cytometry is an essential part of advanced diagnostics and research.

EL-22 and the Engineered Probiotic Platform

EL-22 is part of NorthStrive’s engineered probiotic stage, which is intended to express medicinal proteins directly from genetically engineered Lactobacillus casei. The organization believes this strategy offers a differentiated process of biologic delivery with potential benefits in patient convenience, accessibility, and manufacturability in the various diseases.

The planned FACS program builds on NorthStrive’s wider approaches to advance its live biotherapeutic platform via disciplined, milestone-driven advancement focused on product characterization, production quality, and government readiness.

About NorthStrive Biosciences Inc.

NorthStrive Biosciences Inc., a PMGC Holdings Inc. organization, is a biopharmaceutical company focused on the advancement and acquisition of advanced aesthetic medications. NorthStrive’s lead asset, EL-22, leverages an engineered probiotic strategy to tackle the challenges of conserving muscle while on weight loss management, involving GLP-1 receptor agonists. For more data, visit www.northstrivebio.com.

About PMGC Holdings Inc.

PMGC Holdings Inc. is an extended holding organization that manages and grows its portfolio via strategic acquisitions, investments, and advancement in the different sectors. This company is committed to exploring new opportunities in many sectors to achieve growth and value. For more data, visit www.pmgcholdings.com.

A recent report by Towards Healthcare highlights that the flow cytometry market is witnessing growth because this technology offers the specific possibility to analyze integrated populations of cells for different markers at the same time. Furthermore, to isolate immune cells from peripheral blood, nearly any cell type of any tissue can be isolated, gathered, and analyzed in a single cell suspension. Flow cytometry supports the diagnosis of various conditions, involving infectious diseases and cancer. Flow cytometry is a lab test used to analyze characteristics of cells or particles. Medical care providers apply flow cytometry to diagnose and manage cancer. It supports predicting how aggressive the disease is and determining if the tumor responds to specific treatments.